The drug and biotech sector had a turbulent year in 2024, starting strong but losing momentum in the second half. This ...

If you thought crypto investors need to have strong stomachs, spare a thought for the investors who try their luck in the ...

Mesoblast (NASDAQ:MESO – Get Free Report) was downgraded by investment analysts at Jefferies Financial Group from a “buy” rating to a “hold” rating in a research report issued on Monday, MarketBeat ...

Regenerative medicine company Mesoblast Ltd. received an early Christmas present from the FDA for approval of its allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy, Ryoncil ...

Fintel reports that on December 23, 2024, Jefferies downgraded their outlook for Mesoblast Limited - Depositary Receipt () ...

Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, announced the Food and Drug Administration (FDA) approved Ryoncil (remestemcel-L) as the first mesenchymal ...

Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Mesoblast ( (MESO) ) has shared an update.

Jefferies downgraded Mesoblast (MESO) to Hold from Buy with a price target of A$2.30, up from A$1.10. The firm updated the company’s for the ...

Email Alerts for: Current price: $2.63 Market cap: $3.93bn Current price: $3.01 Current price: $2.31 Current price: $3.69 ...

GEN presents data compiled by Morningstar's Morningstar Direct asset management platform for StockWatch of the top five ...

Mesoblast Ltd (MESO) stock saw a modest uptick, ending the day at $16.76 which represents a slight increase of $4.51 or 36.82% from the prior close of $12.25. The stock opened at $18.68 and touched a ...